CVS Raises Pharmacy Segment Profit Guidance for 2026

Earnings

โดย Zacks Investment Research·

Summary · why it matters

CVS Health is building momentum in its Pharmacy and Consumer Wellness segment, which generated nearly $34 billion in second-quarter revenues and raised its full-year adjusted operating income guidance to at least $6.4 billion, up $220 million from prior guidance. The segment, which includes nearly 9,000 retail locations, benefited from the acquisition of prescription files from 626 former Rite Aid and Bartell Drugs pharmacies, adding more than nine million patients. Same-store pharmacy sales grew approximately 3%, while adjusted operating income rose more than 10% to nearly $1.5 billion, despite headwinds from regulatory-related drug price reductions and pharmacy reimbursement pressure. In related peer updates, DaVita announced a value-based care agreement with Humana for chronic kidney disease patients, and Cardinal Health agreed to acquire two businesses for roughly $360 million in cash. CVS shares have risen 31.1% over the past year, and the company holds a Zacks Rank #3.